J Clin Pharmacol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gillespie, B.
Right arrow Articles by Sullivan, J. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gillespie, B.
Right arrow Articles by Sullivan, J. T.

PHARMACOKINETICS

Effect of Renal Function on the Pharmacokinetics of Palifermin

B. Gillespie, PharmD, P. Zia-Amirhosseini, PhD, M. Salfi, MS, T. Kakkar, PhD, J. Wang, MS, MBA, S. Gupta, PhD, B. Smith, PhD, R. Robson, MB ChB, PhD, FRACP and J. T. Sullivan, MB, ChB, FRACP

From Amgen Inc, Thousand Oaks, California (Dr Gillespie, Dr Zia-Amirhosseini, Ms Salfi, Dr Kakkar, Ms Wang, Dr Gupta, Dr Smith, Dr Sullivan), and Christchurch Clinical Studies Trust, Christchurch, New Zealand (Dr Robson).

Palifermin ({Delta}N23KGF) decreases the incidence, severity, and duration of oral mucositis. The objectives of this open-label study were to evaluate the pharmacokinetics of single-dose palifermin in subjects with varying degrees of renal function. A single 90-mcg/kg intravenous dose of palifermin was administered to 31 subjects with varying levels of renal function (normal to requiring hemodialysis). Pharmacokinetic analyses were conducted using serum palifermin concentrations. There was considerable overlap in mean palifermin serum clearance among the groups, ranging from 318 to 495 mL/h/kg, indicating that the level of renal function did not affect clearance in humans; thus, no dose adjustment of palifermin is indicated for patients with renal dysfunction.

Key Words: Palifermin • renal clearance • keratinocyte growth factor • chronic kidney disease • mucositis

Address for reprints: Address for correspondence: B. Gillespie, PharmD, Amgen Inc, One Amgen Center Drive, MS 38-3-A, Thousand Oaks, CA 91320-1799; e-mail: bgillesp{at}amgen.com.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the American College of Clinical Pharmacology